公开(公告)号：US20140154703A1

公开(公告)日：2014-06-05

申请号：US13978123

申请日：2012-01-06

申请人： Alison Skelley ,  Denis Smirnov ,  Yi Dong ,  Keith D. Merdek ,  Kam Sprott ,  Walter Carney ,  Chunsheng Jiang ,  Richard Huang ,  Ioana Lupascu

发明人： Alison Skelley ,  Denis Smirnov ,  Yi Dong ,  Keith D. Merdek ,  Kam Sprott ,  Walter Carney ,  Chunsheng Jiang ,  Richard Huang ,  Ioana Lupascu

IPC分类号： G01N33/574

CPC分类号： G01N33/574 ,  B01L3/502761 ,  B01L2200/0652 ,  B01L2200/0668 ,  B01L2300/0822 ,  B01L2300/0877 ,  B01L2300/168 ,  B01L2400/086 ,  G01N30/6095

摘要： The invention encompasses methods and devices for diagnosing, theranosing, or prognosing a condition in a patient by enriching a sample in rare cells or other particles. The devices can be a microfluidic device comprising an array of obstacles and one or more binding moieties. The devices and methods can allow for enrichment of cells based on size and affinity, recovery of cells or other particles in locations on the microfluidic device, release of cells or other particles from the microfluidic device, flow of sample through the microfluidic device, and retention of rare cells or other particles from a sample obtained from a patient having a condition.

摘要翻译： 本发明包括通过在罕见细胞或其他颗粒中富集样品来诊断，鉴别或预测病人状况的方法和装置。 装置可以是包含障碍物阵列和一个或多个结合部分的微流体装置。 所述装置和方法可以允许基于大小和亲和力富集细胞，在微流体装置上的位置中回收细胞或其它颗粒，从微流体装置释放细胞或其它颗粒，通过微流体装置的样品流动和保留 从具有条件的患者获得的样品中的稀有细胞或其他颗粒。

公开(公告)号：US20100267058A1

公开(公告)日：2010-10-21

申请号：US12808708

申请日：2008-12-17

申请人： Peter Hamer ,  Stephen P. Bradley ,  Walter Carney

发明人： Peter Hamer ,  Stephen P. Bradley ,  Walter Carney

IPC分类号： G01N33/574 ,  C07K16/30

CPC分类号： G01N33/566 ,  G01N33/57488 ,  G01N2333/91215

摘要： Provided are compositions, methods, and kits relating to the detection of a circulating or soluble form of the KET receptor tyrosine kinase.

摘要翻译： 提供了与检测循环或可溶形式的KET受体酪氨酸激酶相关的组合物，方法和试剂盒。

公开(公告)号：US20080113392A1

公开(公告)日：2008-05-15

申请号：US11965323

申请日：2007-12-27

申请人： Walter Carney ,  Peter Hamer

发明人： Walter Carney ,  Peter Hamer

IPC分类号： G01N33/53 ,  G01N33/48

CPC分类号： G01N33/57484 ,  G01N33/86 ,  G01N2333/8132 ,  G01N2333/9723 ,  G01N2800/52 ,  Y10T436/25

摘要： The present invention describes clinically and medically important methods of examining, screening over time, and monitoring the outcome of a cancer patient who is undergoing treatment or therapy for his or her disease. More specifically, the invention provides a method of monitoring the progression of disease, or the effectiveness of cancer treatment, in a cancer patient by measuring the levels of one or more analytes of the plasminogen activator (uPA) system, namely, uPA, PAI-1 and the complex of uPA:PAI-1, in a sample taken from the cancer patient, preferably, before treatment, at the start of treatment, and at various time intervals during treatment. As a result of performing the method, an increase or elevation in the levels of one or more of the PA system analytes in the cancer patient compared with the levels one or more of the respective PA system analytes in normal control individuals serves as an indicator of cancer advancement or progression and/or a lack of treatment effectiveness for the patient.

摘要翻译： 本发明描述临床和医学上重要的随时间的检查，筛选和监测正在接受治疗或治疗他或她的疾病的癌症患者的结果的重要方法。 更具体地，本发明提供了通过测量纤溶酶原激活物（uPA）系统的一种或多种分析物的水平，即uPA，PAI-1，在癌症患者中监测疾病进展或癌症治疗的有效性的方法， 1和来自癌症患者的样品中的uPA：PAI-1的复合物，优选在治疗前，治疗开始时和治疗期间的各个时间间隔。 作为执行该方法的结果，癌症患者中的一种或多种PA系统分析物的水平的增加或升高与正常对照个体中相应的PA系统分析物中的一个或多个水平相比作为 癌症进展或进展和/或患者缺乏治疗有效性。

公开(公告)号：US20110281279A1

公开(公告)日：2011-11-17

申请号：US12808470

申请日：2008-12-17

申请人： Peter Hamer ,  Stephen P. Bradley ,  Walter Carney

发明人： Peter Hamer ,  Stephen P. Bradley ,  Walter Carney

IPC分类号： G01N33/573 ,  C07K16/40 ,  G01N33/82 ,  G01N21/75 ,  C12Q1/48 ,  G01N21/64

CPC分类号： G01N33/573 ,  G01N33/57415 ,  G01N33/57419 ,  G01N33/57423 ,  G01N33/57434 ,  G01N33/57438 ,  G01N33/57488 ,  G01N2333/91215 ,  G01N2800/56

摘要： Provided are compositions, methods, and kits relating to the detection of a circulating or soluble form of the EphA2 receptor tyrosine kinase.

摘要翻译： 提供了与检测循环或可溶形式的EphA2受体酪氨酸激酶相关的组合物，方法和试剂盒。

公开(公告)号：US20070037224A1

公开(公告)日：2007-02-15

申请号：US11502013

申请日：2006-08-10

申请人： Peter Hamer ,  Walter Carney ,  Leticia Morris ,  James Elting

发明人： Peter Hamer ,  Walter Carney ,  Leticia Morris ,  James Elting

IPC分类号： G01N33/574 ,  G01N33/567

CPC分类号： G01N33/57488 ,  G01N33/57415 ,  G01N33/57419 ,  G01N33/57434 ,  G01N33/57449 ,  G01N33/57492 ,  G01N2333/49 ,  G01N2333/71 ,  G01N2800/52

摘要： The present invention is directed to the detection and quantification of total PDGFR-β in body fluids, particularly serial changes of total PDGFR-β levels in a subject's body fluids. Further, the invention is directed to detecting and quantitatiing total PDGFR-β in conjunction with one or more other proteins, such as, oncoproteins, angiogenic factors, tumor markers, inhibitors, growth factor receptors, metastasis proteins, and tumor suppressors. The disclosed methods are diagnostic/prognostic for diseases, and useful to select therapies for patients with diseases, preferably preneoplastic/neoplastic diseases. The disclosed methods are particularly useful to monitor the status of a patient's disease, and/or to monitor how a patient is responding to a therapy.

摘要翻译： 本发明涉及体液中总PDGFR-β的检测和定量，特别是受试者体液中总PDGFR-β水平的连续变化。 此外，本发明涉及检测和定量总PDGFR-β与一种或多种其它蛋白质，例如癌蛋白，血管生成因子，肿瘤标志物，抑制剂，生长因子受体，转移蛋白和肿瘤抑制剂。 所公开的方法是疾病的诊断/预后，并且可用于选择具有疾病，优选肿瘤前/肿瘤性疾病的患者的治疗。 所公开的方法对于监测患者疾病的状态和/或监视患者如何对治疗作出反应特别有用。